These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 12970136)
1. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Danese S; Katz JA; Saibeni S; Papa A; Gasbarrini A; Vecchi M; Fiocchi C Gut; 2003 Oct; 52(10):1435-41. PubMed ID: 12970136 [TBL] [Abstract][Full Text] [Related]
2. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024 [TBL] [Abstract][Full Text] [Related]
3. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Ludwiczek O; Kaser A; Tilg H Int J Colorectal Dis; 2003 Mar; 18(2):142-7. PubMed ID: 12548417 [TBL] [Abstract][Full Text] [Related]
4. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Danese S; de la Motte C; Sturm A; Vogel JD; West GA; Strong SA; Katz JA; Fiocchi C Gastroenterology; 2003 May; 124(5):1249-64. PubMed ID: 12730866 [TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Menchén L; Marín-Jiménez I; Arias-Salgado EG; Fontela T; Hernández-Sampelayo P; Rodríguez MC; Butta NV Gut; 2009 Jul; 58(7):920-8. PubMed ID: 19039088 [TBL] [Abstract][Full Text] [Related]
6. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Koutroubakis IE; Theodoropoulou A; Xidakis C; Sfiridaki A; Notas G; Kolios G; Kouroumalis EA Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1147-52. PubMed ID: 15489574 [TBL] [Abstract][Full Text] [Related]
7. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Varo N; Libby P; Nuzzo R; Italiano J; Doria A; Schönbeck U Diab Vasc Dis Res; 2005 May; 2(2):81-7. PubMed ID: 16308911 [TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment. Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860 [TBL] [Abstract][Full Text] [Related]
15. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. Fernández Bello I; Álvarez MT; López-Longo FJ; Arias-Salgado EG; Martín M; Jiménez-Yuste V; Rodríguez de la Rúa A; Butta NV Thromb Haemost; 2012 Jan; 107(1):88-98. PubMed ID: 22116092 [TBL] [Abstract][Full Text] [Related]
16. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Aukrust P; Müller F; Ueland T; Berget T; Aaser E; Brunsvig A; Solum NO; Forfang K; Frøland SS; Gullestad L Circulation; 1999 Aug; 100(6):614-20. PubMed ID: 10441098 [TBL] [Abstract][Full Text] [Related]
17. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. Natal C; Restituto P; Iñigo C; Colina I; Díez J; Varo N J Clin Endocrinol Metab; 2008 Jun; 93(6):2319-27. PubMed ID: 18349065 [TBL] [Abstract][Full Text] [Related]
18. Platelet and soluble CD40L in meningococcal sepsis. Inwald DP; Faust SN; Lister P; Peters MJ; Levin M; Heyderman R; Klein NJ Intensive Care Med; 2006 Sep; 32(9):1432-7. PubMed ID: 16810523 [TBL] [Abstract][Full Text] [Related]
19. IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets. Anka Idrissi D; Senhaji N; Aouiss A; Khalki L; Tijani Y; Zaid N; Marhoume FZ; Naya A; Oudghiri M; Kabine M; Zaid Y Arch Pharm Res; 2021 Jan; 44(1):117-132. PubMed ID: 33394309 [TBL] [Abstract][Full Text] [Related]
20. Characterization of soluble CD40 ligand released from human activated platelets. Jin Y; Nonoyama S; Morio T; Imai K; Ochs HD; Mizutani S J Med Dent Sci; 2001 Mar; 48(1):23-7. PubMed ID: 12160239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]